— Know what they know.
Not Investment Advice

EVMN NYSE

Evommune, Inc.
1W: -4.7% 1M: -38.9% 3M: -53.6% YTD: -70.4%
$5.16
+0.03 (+0.58%)
Pre-Market: $5.41 (+0.25, +4.84%)
Weekly Expected Move ±9.6%
$4 $5 $5 $6 $6
NYSE · Healthcare · Biotechnology · Tech Score Strong Sell · Power 32 · $187.3M mcap · 20M float · 4.24% daily turnover · Short 44% of daily vol
Credit Risk of going bust: higher than 76% of companies Debt: 4.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.1%), Evommune, Inc. would be worth roughly what it owes.
Total debt $8.1M against a stock market value of $187.3M.
Distance to default 2.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 113.7%; Altman Z'' 10.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Oct Typical
☁️
Cloudy
+0.0% YTD avg
2026 Now
☁️
Cloudy
Tracking typical
20yr Avg YTD
—
2026 YTD
—
Typical Vol
71%
Annualized
Monthly Weather Forecast
Jan
20yr
💨
+5.7%
100% win 123% vol
Feb
20yr
💨
+43.6%
100% win 278% vol
Mar
20yr
⛈️
-11.6%
0% win 84% vol
Apr
20yr
💨
+3.5%
100% win 74% vol
May
20yr
⛈️
-2.4%
0% win 50% vol
Jun
20yr
⛈️
-42.8%
0% win 161% vol
Jul
20yr
⛈️
-15.3%
0% win 65% vol
Aug
20yr
💨
+12.5%
100% win 73% vol
Sep
20yr
⛈️
-34.8%
0% win 76% vol
Oct
20yr
⛈️
-37.9%
0% win 71% vol
Now: -37.9%
Nov
20yr
💨
+2.4%
100% win 75% vol
Dec
20yr
⛈️
-17.3%
0% win 117% vol

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms